Intensity Therapeutics (INTS) EBITDA (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly EBITDA came in at -$2.5 million in Q1 2026, up 25.57% YoY from -$2.0 million in Q1 2025, and up 19.55% on a QoQ basis from -$3.1 million in Q4 2025.
Intensity Therapeutics (INTS) EBITDA (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of EBITDA data on file, last reported at -$2.5 million in Q1 2026.
- Quarterly EBITDA rose 25.57% year-over-year to -$2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (up 27.12% YoY) and the FY2025 annual result came in at -$12.0 million, up 27.81% from the prior year.
- EBITDA advanced to -$2.5 million in Q1 2026, from -$3.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$1.2 million in Q2 2023 to a low of -$5.1 million in Q2 2024.
- A 5-year average of -$2.8 million and a median of -$2.7 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA tumbled 315.15% — and 2025, when it jumped 46.64%.
- Tracing INTS's EBITDA over 5 years: stood at -$1.5 million in 2022, then slumped by 127.43% to -$3.4 million in 2023, then climbed by 4.45% to -$3.2 million in 2024, then rose by 1.97% to -$3.1 million in 2025, then rose by 19.55% to -$2.5 million in 2026.
- The last three EBITDA figures came in at -$2.5 million (Q1 2026), -$3.1 million (Q4 2025), and -$2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | -3.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.08 Mn |
| Mar 31, 2026 | -2.53 Mn |
| Dec 31, 2025 | -3.14 Mn |
| Sep 30, 2025 | -2.73 Mn |
| Jun 30, 2025 | -2.71 Mn |
| Mar 31, 2025 | -3.39 Mn |
| Dec 31, 2024 | -3.20 Mn |
| Sep 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | -4.74 Mn |
| Dec 31, 2023 | -3.35 Mn |
| Sep 30, 2023 | -2.49 Mn |
| Jun 30, 2023 | -1.22 Mn |
| Mar 31, 2023 | -1.25 Mn |
| Dec 31, 2022 | -1.47 Mn |
| Sep 30, 2022 | -1.77 Mn |
| Jun 30, 2022 | -1.93 Mn |